Display Settings:

Format

Send to:

Choose Destination
Bioorg Med Chem Lett. 2009 Sep 1;19(17):4993-5. doi: 10.1016/j.bmcl.2009.07.071. Epub 2009 Jul 17.

A conformational constraint improves a beta-secretase inhibitor but for an unexpected reason.

Author information

  • 1Department of Medicinal Chemistry, Merck Research Laboratories, Merck & Co., West Point, PA 19486, USA. ivory_hills@merck.com

Abstract

During our ongoing efforts to develop a small molecule inhibitor targeting the beta-amyloid cleaving enzyme (BACE-1), we discovered a class of compounds bearing an aminoimidazole motif. Initial optimization led to potent compounds that have high Pgp efflux ratios. Crystal structure-aided design furnished conformationally constrained compounds that are both potent and have relatively low Pgp efflux ratios. Computational studies performed after these optimizations suggest that the introduction of the constraint enhances potency via additional hydrophobic interactions rather than conformational restriction.

PMID:
19640712
[PubMed - indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Icon for Elsevier Science
    Loading ...
    Write to the Help Desk